Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug pipeline 3Q17

Drug approvals are way up through three quarters, including a number of first-in-class approvals. The first drug targeting a metabolic enzyme mutated in cancer (Celgene's mitochondrial isocitrate dehydrogenase) was approved. The approval of Novartis' highly anticipated CAR-T cancer therapy Kymriah for acute myelogenous leukemia was followed two months later by another: Gilead/Kite's Yescarta for diffuse large B-cell lymphomas. Several gene therapies attained breakthrough drug designation; the first AAV gene therapy approval for a retinal disorder looks likely before year's end.

Historic US regulatory approvals by lead indication

Notable regulatory approvals (3Q17)

Notable regulatory setbacks (3Q17)

Notable clinical trial results (3Q17)

Notable upcoming regulatory catalysts (4Q17)

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. Drug pipeline 3Q17. Nat Biotechnol 35, 1125 (2017). https://doi.org/10.1038/nbt.4032

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing